

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,592,150 B2  
APPLICATION NO. : 10/728227  
DATED : September 22, 2009  
INVENTOR(S) : Nir Dotan et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 27, Line 12, Claim 10, “can antibody in said sample is an IgC isotype antibody.” should read -- can antibody in said sample is an IgG isotype antibody. --

Column 27, Lines 25-26, Claim 12, “as having Crohn’s disease if said ALCA and said polysaccharide ( $\beta$  1-3) Glucan antibody levels are elevated in said,” should read -- as having Crohn’s disease if said ALCA and said polysaccharide  $\beta$ -D (1-3) Glucan antibody levels are elevated in said --

Column 27, Line 62, Claim 18, “( $\alpha$  1-3) [Man ( $\alpha$  1-6)] Man ( $\alpha$ ) antibody, anti-Man ( $\alpha$  1-2),” should read -- ( $\alpha$  1-3) Man ( $\alpha$ ) antibody, anti-Man ( $\alpha$  1-3)[Man ( $\alpha$  1-6)] Man ( $\alpha$ ) antibody, anti-Man ( $\alpha$  1-2) --

Column 29, Line 4, Claim 35, “detected with an enzyme-linked inununoabsorbent assay,” should read -- detected with an enzyme-linked immunoabsorbent assay --

Column 29, Line 11, Claim 37, “GlcNAc ( $\beta$ ) antibody (ACCA) or an anti-polysaceharide  $\beta$ -D,” should read -- GlcNAc ( $\beta$ ) antibody (ACCA) or an anti-polysaccharide  $\beta$ -D --

Column 29, Line 14, Claim 37, “anti-polysaceharide  $\beta$ -D (1-3) Glucan antibody levels are,” should be -- anti-polysaccharide  $\beta$ -D (1-3) Glucan antibody levels are --

Column 29, Lines 36-37, Claim 42, “comprises detecting a level of an anti-GlcNAc ( $\beta$  1-4) GlcNAc ( $\beta$ ) antibody (ACCA) and an anti-polysaceharide,” should be -- comprises detecting a level of an anti-GlcNAc ( $\beta$  1-4) GlcNAc ( $\beta$ ) antibody (ACCA) and an anti-polysaccharide --

Column 30, Line 29, Claim 50, “IgG ALCA, IgC ASCA, or IgA ASCA antibodies are” should read -- IgG ALCA, IgG ASCA, or IgA ASCA antibodies are --

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 7,592,150 B2  
APPLICATION NO. : 10/728227  
DATED : September 22, 2009  
INVENTOR(S) : Nir Dotan et al.


Page 2 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 30, Line 57, Claim 53, "GlcNAc ( $\beta$ ) glycan, said Glc( $\beta$  1-3) Glc ( $\beta$ ), said mannan, and" should read -- GlcNAc ( $\beta$ ), said Glc( $\beta$  1-3) Glc ( $\beta$ ), said mannan, and --

Signed and Sealed this

Tenth Day of November, 2009

A handwritten signature in black ink, reading "David J. Kappos". The signature is written in a cursive, flowing style.

David J. Kappos  
*Director of the United States Patent and Trademark Office*